Catalog No.
EHH02202
Expression system
Mammalian Cells
Species
Homo sapiens (Human)
Protein length
Pro21-Gln167
Predicted molecular weight
19.75 kDa
Nature
Recombinant
Concentration
3 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
Q15116
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Liquid
Storage buffer
PBS pH 7.4
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279
Armored human CAR Treg cells with PD1 promoter-driven IL-10 have enhanced suppressive function., PMID:40512855
The efficacy and safety of regorafenib/fruquintinib combined with PD-1/PD-L1 for metastatic colorectal cancer: a meta-analysis based on single-arm studies., PMID:40510355
Arsenic Trioxide Enhances the Efficacy of PD-1 Inhibitors in Hepatocellular Carcinoma by Inducing Immunogenic Cell Death via the ROS/ERS Pathway., PMID:40504080
PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution., PMID:40503235
5-ALA Assisted Surgery of Human Glioblastoma Samples Reveals an Enrichment of T Cells Expressing PD-1 and CD103 in the Intermediate and Marginal Layers., PMID:40498413
PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone as the first line treatment for advanced biliary tract cancer: a pooled analysis of KEYNOTE-966 and TOPAZ-1 trails., PMID:40495210
Immunohistochemical expression of PD1, LAG3, and CTLA4 in diffuse large B cell lymphoma, clinicopathological correlation, and prognostic value., PMID:40481915
Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis., PMID:40481442
ALG3 as a prognostic biomarker and mediator of PD-1 blockade resistance in hepatocellular carcinoma., PMID:40475760
An exploration of the initiation time and patient selection of PD-1 inhibitors/PD-1 inhibitors combined with chemotherapy as salvage therapy in R/R DLBCL patients after anti-CD19-CAR T-cell therapy., PMID:40474425
Targeting CD39 boosts PD-1 blockade antitumor therapeutic efficacy via strengthening CD8 + TILs function and recruiting B cells in cervical cancer., PMID:40462160
Synergistic effects of PD-1 antibody and chemotherapy followed by surgery-centric local treatment in patients with limited-metastatic gastric or gastroesophageal adenocarcinoma (ROSETTE trial): an open-label, single-center, randomized phase 2 trial., PMID:40452026
Circulating immunoregulatory B cell and autoreactive antibody profiles predict lack of toxicity to anti-PD-1 checkpoint inhibitor treatment in advanced melanoma., PMID:40449958
Bidirectional interaction between epithelial-mesenchymal transition and PD-1/PD-L1 expression in tongue carcinogenesis., PMID:40446517
Top advances of the year: Developments of immunotherapy in cutaneous squamous cell carcinoma, 2023-2024., PMID:40445861
Stabilized iRGD modification enhances NY-ESO-1 TCR-T infiltration in solid tumors and synergizes with PD-1 blockade., PMID:40445421
The promise of PD1/PDL1 targeted immunotherapy in locally advanced cervical cancer: a game-changer for patients outcome?, PMID:40433369
Serum sPD-1 as a marker of T cell exhaustion in ART-naïve, ART-experienced, and intestinal parasite co-infected HIV-positive adults at the university of Gondar comprehensive specialized hospital, Northwest Ethiopia, 2024., PMID:40426096
Basic rules to respond to PD-1 blockade cancer immunotherapy., PMID:40425230
The Spatial Proximity of CD8+ FoxP3+PD-1+ Cells to Tumor Cells: A More Accurate Predictor of Immunotherapy Outcomes in Advanced Non-Small-Cell Lung Cancer., PMID:40422521
Which sarcoma requires PD1/PDL1 inhibitors, and what should be the best scheme? Present status and next steps., PMID:40421971
[A novel fully human LAG-3 monoclonal antibody LBL-007 combined with PD-1 antibody inhibits proliferation, migration and invasion of tumor cells via blocking NF-κB pathway]., PMID:40415618
Efficacy, safety and exploratory analysis of neoadjuvant tislelizumab (a PD-1 inhibitor) plus nab-paclitaxel followed by epirubicin/cyclophosphamide for triple-negative breast cancer: a phase 2 TREND trial., PMID:40414961
Clinical benefit of continuation of PD-1 inhibitors after progression on first-line chemoimmunotherapy in metastatic gastric cancer and biomarker exploration., PMID:40413463
Impact of rheumatoid factors on the function of therapeutic monoclonals specific for PD-1/PD-L1., PMID:40411581
The role of PD-1/PD-L1 in overshooting osteoclastogenesis in periprosthetic joint infections., PMID:40404949
Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study., PMID:40404633
Blockade of CLEVER-1 restrains immune evasion and enhances anti-PD-1 immunotherapy in gastric cancer., PMID:40404204
Low-Dose Anti-PD1 Immune Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Systematic Review., PMID:40403200
High-Risk HPV Oncoproteins and PD-1/PD-L1 Interplay., PMID:40400495
CGRP, PD-1 and PD-L1 as Biomarkers for PICC-Related Bloodstream Infections in Breast Cancer Patients., PMID:40398661
NECTIN4 regulates the cell surface expression of CD155 in non-small cell lung cancer cells and induces tumor resistance to PD-1 inhibitors., PMID:40392373
[Autopsy of immune related cardiovascular adverse reactions caused by PD-1 inhibitors: a case report]., PMID:40389345
Adaptive immune response and PD-1/ PD-L1 status in chemotherapy treated high grade serous carcinoma is dependent on chemotherapy response score., PMID:40389122
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology., PMID:40388341
Case Report: Abscopal effect in a patient with refractory metastatic hepatocellular carcinoma treated with stereotactic body radiotherapy and PD-1 inhibitor., PMID:40386774
Cracking Chordoma's Conundrum: Immune Checkpoints Provide a Potential Modality., PMID:40386066
A novel pH-sensitive nanoparticles encapsulating anti-PD-1 antibody and MDK-siRNA overcome immune checkpoint blockade resistance in HCC via reshaping immunosuppressive TME., PMID:40380202
Case Report: Combined PD-1 and tyrosine kinase blockade stabilizes refractory pancreatic cancer guided by the spatial structure of tumor immune microenvironment., PMID:40376004
Improved efficacy of concurrent anti-PD1 antibody plus AVD versus ABVD in patients with newly diagnosed early unfavorable and advanced stage classic Hodgkin lymphoma: a retrospective matched cohort study., PMID:40372486
Impact of Exposure to Benzodiazepines on Adverse Effects and Efficacy of PD-1/PD-L1 Blockade in Patients With Non-Small Cell Lung Cancer., PMID:40368363
Advances in cancer immunotherapy using small-molecular inhibitors targeting the PD-1/PD-L1 interaction., PMID:40367914
Definitive chemoradiotherapy combined with anti-PD-1 immunotherapy for inoperable esophageal squamous cell carcinoma: a multicenter real-world study., PMID:40367097
Clinical manifestations and risk factors of immune-related thyroid adverse events in patients treated with PD-1 inhibitors: a case-control study., PMID:40356893
Development of a prediction model integrating PD-1 and ICOS for early differential diagnosis between autoimmune and viral encephalitis., PMID:40352922
CD8+ T cells in breast cancer tumors and draining lymph nodes: PD-1 levels, effector functions and prognostic relevance., PMID:40351118
N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1., PMID:40346531
Intrathecal administration of PD-1 inhibitor combined with pemetrexed for leptomeningeal metastases from breast cancer: a case report., PMID:40342406
Spatial transcriptomics reveals tumor microenvironment heterogeneity in EBV positive diffuse large B cell lymphoma., PMID:40335578
Mixing it up: boosting responses with immunotherapy combinations., PMID:40335428
For research use only. Not for human or drug use.
